found elevated levels of copper in various locations, but usually failed to realize its significance. After Fleischer in 1912 observed elevated copper in the cornea, Rumpel in 1913 [11] , Vogt in 1929 [12] , and Haurowitz in 1930 [13] observed elevated hepatic copper levels in Wilson's disease patients. Glazebrook in 1945 [14] and Cumings in 1948 [15] detected elevated copper in both liver and brain tissue in patients, and for the first time, began to discuss an etiological role for copper. We'll return to those two papers in a moment. In 1948, Mandelbrote [16] detected an elevated urine copper in a patient with Wilson's disease, and showed that urinary copper increased with British Antilewisite (BAL) injections.
Other important historical milestones include the first specific anticopper treatment of Wilson's disease patients with BAL injections in 1951 by Cumings [17] , the discovery of a low level in the plasma of Wilson's disease patients of the coppercontaining protein, ceruloplasmin in 1952 by two sets of investigators (Bearn and Kunkel [18] , and Scheinberg and Gitlin [19] , and the working out of autosomal recessive inheritance in 1960 by Bearn [20] . In 1944, Ravesteyn [21] had gone a long way towards showing that copper balance in normal people is regulated by biliary excretion of copper, and in 1974 Frommer [22] demonstrated that the defect in Wilson's disease was a failure of biliary copper excretion.
Oral anticopper therapy ushered in a management era that was much improved for these patients and began with the introduction of penicillamine, a chelating agent that enhances urinary excretion of copper, by Walshe, in 1956 [23] . Walshe followed this up by introducing an alternative chelator, trientine, in 1982 [24] . Schouwink's thesis at the University of Amsterdam in 1961 [25] discussed treatment of two patients with zinc, but went unnoticed because it was not published in the general literature. In 1983, we published our first paper on zinc therapy in Wilson's disease [26] , and have gone on to publish over 50 papers on this topic, culminating in the U.S. FDA approval of zinc acetate for Wilson's disease in 1997. In 1987, we identified the frequent problem of neurological worsening of neurologically-presenting patients when treated with penicillamine [27] , and in 1991 introduced tetrathiomolybdate as an initial therapy for this type of patient [28] .
In 1993, the causative gene for Wilson's disease, known as ATP7B, was identified by three groups working independently (Bull et al. [4] ; Tanzi et al. [5] ; Yamaguchi et al. [6] ). The LEC rat, first shown by Li et al. in 1991 [29] to sequester hepatic copper, is an ideal animal model because it has been shown by Wu et al. [30] and Sasaki et al. [31] in 1994, to involve the rat homologue of ATP7B. The same is true of the "toxic milk" mouse, as shown by Theophilos et al. in 1996 [32] .
With so many important contributions to this disease of copper toxicity, how do we choose the most important to honor as a landmark article? We decided that the seminal studies regarding copper in this disease were those that identified an etiological role for copper in causing the disease. It was from the basic concept of copper causation that specific anticopper therapies were developed, and the gene itself cloned. (Gene cloning led from cloning ATP7A, the causative gene in Menke's disease, already known to be another disorder of copper metabolism.)
In looking back at the trail of papers relating copper abnormalities to Wilson's disease, we believe two papers were most critical in developing the concept of a copper etiology. These are the papers by Glazebrook (Wilson's disease. Edinburgh Med J 52:83-87, 1945 [14] ) and Cummings (The copper and iron content of brain and liver in the normal and in hepatolenticular degeneration. Brain 71:410-415, 1948 [15] ). These two papers are reproduced here, to honor their contributions.
The paper by Glazebrook [14] describes two cases of Wilson's disease. The second patient died in hospital and an autopsy was carried out. While the patient was still alive, the author had shown that the patient's blood copper was elevated. At autopsy, he was able to show that the copper was elevated in both the liver and basal ganglia of the brain, and to a lesser extent the brain cortex. Glazebrook goes on in this paper to discuss how copper toxicity might damage the brain. He points out that "copper is a powerful inhibitor of enzymic activity, even in dilute solution," and "the exceptionally rich blood supply of the basal ganglia affords an indication of the great respiratory demands of these tissues, and they are in fact peculiarly susceptible to damage by inhibitors of enzymic activity, such as cyanide and carbon monoxide." Perhaps we can still learn from these remarks. We still don't understand the special sensitivity to copper of these regions of the brain, and perhaps Glazebrook's insight should lead us into further thinking about the special metabolic features of these regions.
More than this, however, was the particularly insightful remark in the summary, which happens to be the last sentence in the paper: "Inability to excrete copper may be the liver dysfunction responsible for the production of lenticular degeneration." This statement, made in this 1945 paper [14] , turns out to be right on target. It would be 29 years later before it was shown that a defect in biliary excretion of copper caused Wilson's disease [22] .
The second paper we honor is that of Cumings [15] . This paper was published three years after that of Glazebrook, and confirmed the elevated copper in the livers and brains of Wilson's disease patients, but in a larger number of patients. This paper continued developing the theme of the etiological role of copper, "By analogy, it would also seem possible that hepatolenticular degeneration is an inborn error in mineral metabolism." And, "The possibility that the condition is a metabolic disorder similar to that of haemochromatosis has been discussed."
But perhaps the most important contribution in this paper [15] is the movement of Cumings' thinking toward using the etiological role of copper as a reason to consider anticopper therapy. For example, talking about anticopper therapy with BAL, he said, "It might also be used in an attempt to reduce the copper content of the liver and brain, and possibly thereby to prevent further damage to the tissues." Cumings then initiated a BAL therapy trial [17] , with some success, and therapy of this disease, later to become so successful, was off and running.
